708-15-6

Usage

Uses

Used in Pharmaceutical Development:
2-AMINO-8-METHOXYQUINAZOLINE is used as a building block for the development of pharmaceutical drugs due to its unique chemical structure and potential pharmacological properties.
Used in Research Laboratories:
In chemical and pharmaceutical laboratories, 2-AMINO-8-METHOXYQUINAZOLINE is used as a research reagent, facilitating the study of its chemical properties and potential applications in medicinal chemistry.
Used in Medicinal Chemistry:
2-AMINO-8-METHOXYQUINAZOLINE is utilized in the field of medicinal chemistry for the development of new therapeutic agents for various medical conditions, leveraging its chemical properties to enhance research and innovation in drug discovery.

InChI:InChI=1/C9H9N3O/c1-13-7-4-2-3-6-5-11-9(10)12-8(6)7/h2-5H,1H3,(H2,10,11,12)

Upstream product

• 70127-96-7 2-amino-3-methoxy-benzaldehyde 
• 50-01-1 guanidine hydrochloride 
• 53055-05-3 3-methoxy 2-nitrobenzaldehyde 
• 944060-66-6 2-chloro-8-methoxyquinazoline 

Downstream Products

• 659730-14-0 2-amino-8-hydroxyquinazoline 

Relevant academic research and scientific papers

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate

A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl} -acetamide; AMG 517) was selected for further evaluation in human clinical trials.

NEUROLOGICALLY-ACTIVE COMPOUNDS

The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.